Figure S1: Cellular viability assays of co-cultured a SUM149 and b SUM159 cells on the bottom chambers with LECs on the top chamber in treatment of various concentration of maraviroc and d tocilizumab (Transwell plates). The cellular viability was measured for 72 h by MTT assay (*P<0.001, n=3). c Crystal violet staining assay was performed in treatment of maraviroc (2 uM), tocilizumab (200 ug/ml), and the combination of maraviroc and tocilizumab.
Figure S2: Migration assay of a SUM149 and b SUM159 cells (top chamber) in CM (bottom chamber) from LECs co-cultured with two TNBC cells with treatment of maraviroc, tocilizumab, and the combination. The migrated cells were counted for 24 h by the crystal violet staining. The representative migration was shown. (**P<0.001, n=3). c Migration assay of TNBC cells in CM from LECs co-cultured with TNBC cells with tocilizumab pre-treatment. The pre-labeled with Cell Tracker Green and the migration was measured using the Oris cell migration kit. ELISA of human CCL5 (Quantikine ELISA, R&D System) in the CM of LECs co-cultured with d SUM149 and e SUM159 cells pre-treated tocilizumab. (*P<0.001, n=3).